Reactions 1704, p342 - 2 Jun 2018 Hyperbilirubinaemia and severe asthenia: 2 case reports In a prospective, observational cohort study of 204 patients, two patients [ages and sexes not stated] were described, who developed severe asthenia or hyperbilirubinaemia during treatment with simeprevir and sofosbuvir for chronic hepatitis C [durations of treatments to reactions onsets not stated]. The patients with chronic hepatitis C started receiving treatment with oral sofosbuvir 400mg daily and oral simeprevir 150mg daily. Subsequently, one patient developed severe asthenia and second patient developed severe hyperbilirubinaemia with a bilirubin level of 10 mg/dL. The treatment with simeprevir and sofosbuvir was stopped in the patient having hyperbilirubinaemia, after which an improvement was noted [not all outcomes stated]. Author comment: [Asthenia] was the most common adverse effect, reported by 46 patients (22.5%). It was mild in 38 patients, moderate in seven and severe in one. The causes that led to the suspension of treatment were. . .severe hyperbilirubinaemia (10 mg/dL). In one patient it was decided to suspend treatment for this reason, with subsequent improvement. Moreno-Planas JM, et al. Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir. Enfermedades Infecciosas Y Microbiologia Clinica 36: 277-283, No. 5, May 2018. Available from: URL: http://doi.org/10.1016/j.eimc.2017.05.001 [Spanish; Summarised from a translation] - Spain 803323161 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera